GlassScriptPhysician profile
Mary S Goswitz
NPI 1033127055
$2,483.55
in general payments reported to CMS, 2019-2025
43 companies · $387 in 2025
The $387 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $21.63 · 2022: $321 · 2023: $706 · 2024: $838 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,932.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,931.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $263.65 | 2022-2024 | Imfinzi, Enhertu |
| Sobi, INC | $240.93 | 2022-2024 | |
| Pfizer INC. | $185.84 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $177.78 | 2023-2025 | Keytruda, Lynparza |
| Incyte Corporation | $163.81 | 2019-2024 | Jakafi, Pemazyre, Monjuvi |
| Daiichi Sankyo INC. | $103.73 | 2022-2024 | Enhertu |
| Emd Serono, INC. | $84.91 | 2023-2024 | Bavencio |
| Azurity Pharmaceuticals, INC. | $76.44 | 2024-2025 | Vivimusta, Danziten |
| Taiho Oncology, INC. | $75.26 | 2022-2023 | |
| Boston Scientific Corporation | $73.08 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $70.73 | 2022-2024 | Onivyde, Somatuline Depot |
| Regeneron Healthcare Solutions, INC. | $65.39 | 2022-2025 | Libtayo |
| Mirati Therapeutics, INC. | $64.70 | 2023-2024 | Krazati |
| Tactile Systems Technology INC | $59.00 | 2019 | |
| Myriad Genetic Laboratories, INC. | $57.21 | 2023 | Myrisk, Prolaris |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $46.00 | 2019-2023 | Lumakras |
| Cti Biopharma Corp. | $45.67 | 2023 | Vonjo |
| Tempus Ai, INC | $42.57 | 2024-2025 | Xt Cdx |
| Morphosys, US INC. | $40.43 | 2022-2023 | Monjuvi |
| Beigene USA, INC. | $38.10 | 2023-2024 | Brukinsa |
| Deciphera Pharmaceuticals INC. | $35.34 | 2025 | Romvimza, Qinlock |
| Novartis Pharmaceuticals Corporation | $34.95 | 2024 | |
| Alexion Pharmaceuticals, INC. | $34.91 | 2022-2023 | Ultomiris |
| Sumitomo Pharma America, INC. | $34.19 | 2024 | Orgovyx |
| Seagen INC. | $33.56 | 2022-2023 | Padcev |
| Janssen Biotech, INC. | $24.12 | 2023 | Imbruvica, Darzalex |
| Stemline Therapeutics INC. | $23.71 | 2024 | Orserdu |
| Puma Biotechnology, INC. | $22.76 | 2023 | |
| Aveo Pharmaceuticals, INC. | $22.47 | 2023 | Fotivda |
| E.R. Squibb & Sons, L.L.C. | $21.66 | 2025 | Opdualag |
| Celgene Corporation | $21.63 | 2020 | |
| Beone Medicines USA, INC. | $19.43 | 2025 | Brukinsa |
| Telix Pharmaceuticals | $17.96 | 2023 | Illuccix |
| Karyopharm Therapeutics INC. | $17.68 | 2023 | Xpovio |
| Pharmaessentia USA Corporation | $17.27 | 2023 | Besremi |
| Sirtex Medical INC | $17.25 | 2023 | Sir-Spheres Microspheres |
| Curium US LLC | $16.84 | 2022 | |
| Neotract INC. | $16.77 | 2019 | |
| Jazz Pharmaceuticals INC. | $16.59 | 2019 | |
| Genzyme Corporation | $16.35 | 2022 | |
| Eisai INC. | $14.94 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.61 | 2019 | |
| Genentech USA, INC. | $13.33 | 2024 | Tecentriq, Tecentriq Hybreza, Alecensa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Goswitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.